Abstract
BackgroundAgonistic 4-1BB monoclonal antibodies were preclinically validated as promising cancer immunotherapies, both as monotherapy and as potentiators of the activity of PD-(L)1–blocking agents. However, toxicity and a narrow therapeutic window...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have